URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Lisa Demeter

Concepts (278)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of pubs Most recent pub Pubs by all authors Concept score Why?
HIV-1
66
1995
593
11.510
Why?
HIV Infections
46
1995
616
7.640
Why?
Anti-HIV Agents
35
1996
182
7.620
Why?
HIV Reverse Transcriptase
23
1995
129
4.760
Why?
Reverse Transcriptase Inhibitors
25
1995
93
4.720
Why?
Drug Resistance, Viral
21
2003
65
4.320
Why?
Virus Replication
21
1992
307
4.310
Why?
HIV Protease Inhibitors
11
1997
58
3.120
Why?
Mutation
21
1995
1226
2.550
Why?
Drug Monitoring
6
2003
41
2.520
Why?
Acquired Immunodeficiency Syndrome
10
1995
201
2.260
Why?
RNA, Viral
26
1990
294
2.200
Why?
Zidovudine
14
1995
71
1.980
Why?
Indinavir
8
1997
18
1.930
Why?
Drug Resistance, Microbial
14
1997
120
1.640
Why?
Ribonuclease H
5
1999
98
1.390
Why?
Delavirdine
6
1997
15
1.380
Why?
HIV
6
2001
83
1.320
Why?
Viral Load
15
1997
141
1.290
Why?
Benzoxazines
7
2003
35
1.250
Why?
Lamivudine
5
1997
28
1.230
Why?
CD4 Lymphocyte Count
19
1995
160
1.190
Why?
DNA, Viral
12
1990
310
1.190
Why?
Microbial Sensitivity Tests
8
1995
170
1.180
Why?
Humans
76
1990
37165
0.980
Why?
Recombination, Genetic
2
2004
182
0.970
Why?
Antiretroviral Therapy, Highly Active
7
2003
66
0.970
Why?
HIV Protease
3
2004
22
0.910
Why?
Papillomaviridae
7
1990
137
0.900
Why?
Dideoxynucleosides
3
2003
15
0.860
Why?
Drug Therapy, Combination
16
1995
397
0.810
Why?
RNA-Directed DNA Polymerase
2
1995
81
0.810
Why?
Tumor Virus Infections
4
1992
61
0.750
Why?
Piperazines
4
1995
76
0.740
Why?
Adult
36
1990
11572
0.720
Why?
Oxazines
3
2003
30
0.710
Why?
Cell Line
11
1999
1623
0.690
Why?
Genes, Viral
4
1998
86
0.670
Why?
Didanosine
3
1995
21
0.660
Why?
Mutagenesis, Site-Directed
5
2000
306
0.640
Why?
Flow Cytometry
2
2006
603
0.600
Why?
Female
39
1990
20222
0.570
Why?
Male
33
1990
20139
0.540
Why?
Models, Biological
3
2006
1029
0.520
Why?
DNA Replication
1
2006
207
0.510
Why?
Gene Products, gag
1
2004
23
0.500
Why?
Genome, Viral
1
2004
36
0.490
Why?
Genotype
10
1998
473
0.490
Why?
Leukocytes, Mononuclear
2
1998
112
0.490
Why?
Antiviral Agents
4
1995
170
0.470
Why?
Sequence Analysis, DNA
3
1998
169
0.450
Why?
AIDS-Related Opportunistic Infections
1
2002
64
0.420
Why?
Treatment Outcome
10
1996
2671
0.420
Why?
Middle Aged
16
1993
10013
0.420
Why?
Base Sequence
7
1995
1721
0.410
Why?
Mutation, Missense
3
2010
89
0.400
Why?
Pneumonia, Pneumocystis
1
2002
121
0.390
Why?
Laboratories
2
1998
26
0.380
Why?
Phenotype
7
1997
756
0.380
Why?
HIV Envelope Protein gp120
1
2000
48
0.370
Why?
Cysteine
1
2001
154
0.370
Why?
Tyrosine
1
2001
145
0.370
Why?
Defective Viruses
1
1999
15
0.350
Why?
Cells, Cultured
8
1992
2589
0.350
Why?
Interferon-gamma
4
2000
341
0.330
Why?
Uterine Cervical Neoplasms
2
1992
125
0.330
Why?
Kinetics
4
1999
1471
0.320
Why?
Papillomavirus Infections
2
1994
55
0.320
Why?
Anti-Retroviral Agents
3
2003
22
0.290
Why?
Carcinoma in Situ
2
1992
40
0.290
Why?
Condylomata Acuminata
5
1990
53
0.290
Why?
Indoles
1
1997
104
0.280
Why?
Nelfinavir
3
2003
7
0.280
Why?
Reagent Kits, Diagnostic
2
2004
15
0.270
Why?
HIV Core Protein p24
3
1998
33
0.260
Why?
Carcinoma, Squamous Cell
2
1992
238
0.260
Why?
Papilloma
1
1994
13
0.250
Why?
Drug Administration Schedule
3
2009
374
0.240
Why?
Prevalence
3
1993
582
0.240
Why?
Double-Blind Method
6
1990
996
0.240
Why?
Clinical Trials as Topic
3
2000
685
0.240
Why?
Penile Neoplasms
1
1993
16
0.230
Why?
Keratinocytes
1
1994
103
0.230
Why?
Codon
3
1998
69
0.230
Why?
Antigens, Neoplasm
1
1994
109
0.230
Why?
Treatment Failure
4
2000
131
0.220
Why?
Point Mutation
2
1999
178
0.210
Why?
Receptors, Immunologic
1
1992
49
0.210
Why?
Molecular Sequence Data
4
1995
2046
0.210
Why?
Virus Cultivation
2
1992
29
0.200
Why?
HeLa Cells
2
1999
299
0.200
Why?
Computer Simulation
2
2008
304
0.190
Why?
Follow-Up Studies
4
1990
1889
0.190
Why?
Virology
1
2010
20
0.190
Why?
5' Untranslated Regions
2
1999
26
0.190
Why?
CD8-Positive T-Lymphocytes
2
1997
229
0.190
Why?
HIV Envelope Protein gp41
1
2010
4
0.190
Why?
Sensitivity and Specificity
4
2003
914
0.180
Why?
Virulence
1
2010
153
0.180
Why?
Virus Latency
1
2010
15
0.180
Why?
Nuclear Proteins
1
1994
335
0.180
Why?
Virion
1
2010
66
0.180
Why?
Pregnancy Complications, Infectious
3
1995
84
0.180
Why?
Linear Models
2
2006
248
0.170
Why?
Software
1
2010
129
0.170
Why?
Internet
1
2010
106
0.170
Why?
Polymerase Chain Reaction
5
1997
597
0.170
Why?
Virus Physiological Phenomena
1
2008
5
0.160
Why?
T-Lymphocytes
3
2001
564
0.160
Why?
Biometry
1
2008
43
0.160
Why?
CD4-Positive T-Lymphocytes
2
1997
298
0.160
Why?
Antigens, Fungal
2
2002
35
0.160
Why?
Reproducibility of Results
3
1998
903
0.160
Why?
Lymphocyte Count
2
1997
56
0.160
Why?
Peptide Fragments
1
2010
307
0.160
Why?
RNA, Transfer, Amino Acyl
2
2001
13
0.150
Why?
Mice, SCID
1
2007
171
0.150
Why?
Stavudine
2
1997
5
0.150
Why?
Cervical Intraepithelial Neoplasia
1
2006
26
0.140
Why?
Developing Countries
1
2006
41
0.140
Why?
RNA, Transfer, Lys
1
2006
11
0.140
Why?
Antigens, Thy-1
1
2006
61
0.140
Why?
Mathematics
1
2006
149
0.140
Why?
Pregnancy
5
1995
1941
0.140
Why?
Interferons
2
1996
47
0.140
Why?
Mice
3
1992
6206
0.140
Why?
Genes, Reporter
1
2006
209
0.130
Why?
Amino Acid Substitution
1
2006
133
0.130
Why?
Research Design
1
2008
340
0.130
Why?
Animals
4
1992
16416
0.130
Why?
T-Lymphocytes, Cytotoxic
1
2006
147
0.130
Why?
DNA Primers
1
2006
422
0.130
Why?
Nucleosides
1
2004
11
0.130
Why?
RNA, Messenger
1
1992
1893
0.130
Why?
Templates, Genetic
1
2004
99
0.120
Why?
Disease Progression
3
1997
533
0.120
Why?
COS Cells
1
2004
165
0.120
Why?
Cercopithecus aethiops
1
2004
166
0.120
Why?
Sequence Alignment
1
2004
193
0.120
Why?
Adenine
1
2003
46
0.120
Why?
Cloning, Molecular
1
2004
494
0.110
Why?
Mutagenesis
2
1999
142
0.110
Why?
Oncogene Proteins, Viral
2
1992
44
0.110
Why?
Retrospective Studies
4
1995
2302
0.110
Why?
Aged
4
1999
7392
0.110
Why?
DNA, Fungal
1
2002
81
0.110
Why?
Proviruses
2
1997
11
0.100
Why?
Pneumocystis
1
2002
102
0.100
Why?
Clinical Protocols
1
2001
107
0.100
Why?
Vaccines, DNA
1
2001
22
0.100
Why?
3' Untranslated Regions
1
2001
32
0.100
Why?
Adenosine
1
2001
90
0.100
Why?
Papillomavirus Vaccines
1
2001
26
0.100
Why?
Hydrolysis
1
2001
153
0.100
Why?
Heteroduplex Analysis
1
2000
3
0.100
Why?
Dehydroepiandrosterone Sulfate
1
2000
7
0.100
Why?
Sequence Analysis
1
2000
27
0.100
Why?
Viral Vaccines
1
2001
105
0.090
Why?
Practice Guidelines as Topic
1
2003
319
0.090
Why?
Guidelines as Topic
1
2001
91
0.090
Why?
Autonomic Nervous System
1
2000
70
0.090
Why?
Evolution, Molecular
1
2000
63
0.090
Why?
Predictive Value of Tests
1
2002
609
0.090
Why?
Logistic Models
1
2001
626
0.090
Why?
Gene Amplification
1
1998
30
0.080
Why?
Drug Eruptions
1
1998
29
0.080
Why?
Specimen Handling
2
2006
72
0.080
Why?
Drug Resistance
2
1995
100
0.080
Why?
Interferon-alpha
2
1990
85
0.070
Why?
Immunotherapy
1
1997
88
0.070
Why?
Cell Proliferation
2
2008
520
0.070
Why?
Biopsy
1
1996
384
0.060
Why?
Infectious Disease Transmission, Vertical
1
1995
48
0.060
Why?
Cohort Studies
1
1998
984
0.060
Why?
Genital Neoplasms, Male
1
1994
14
0.060
Why?
Genital Neoplasms, Female
1
1994
31
0.060
Why?
Laryngeal Neoplasms
1
1994
19
0.060
Why?
Proliferating Cell Nuclear Antigen
1
1994
46
0.060
Why?
Immunoenzyme Techniques
1
1994
214
0.060
Why?
Virus Integration
1
1993
23
0.060
Why?
Blotting, Southern
1
1993
103
0.060
Why?
Regression Analysis
3
1990
539
0.060
Why?
In Situ Hybridization
1
1994
332
0.060
Why?
Area Under Curve
2
2000
64
0.060
Why?
Vaginal Smears
2
1999
69
0.060
Why?
Receptors, Laminin
1
1992
7
0.050
Why?
Warts
1
1992
23
0.050
Why?
Nucleic Acid Hybridization
1
1992
179
0.050
Why?
Pyridazines
1
2011
7
0.050
Why?
Nevirapine
1
2011
9
0.050
Why?
Patient Selection
2
2003
223
0.050
Why?
Neoplasm Invasiveness
1
1992
160
0.050
Why?
Blotting, Northern
1
1992
304
0.050
Why?
RNA, Complementary
1
2010
13
0.050
Why?
Antigens, Bacterial
1
2011
93
0.050
Why?
Antigens, Viral
1
2011
144
0.050
Why?
Calibration
1
2010
44
0.050
Why?
Interferon Type I
1
1990
38
0.050
Why?
Ribonuclease H, Human Immunodeficiency Virus
1
2010
2
0.050
Why?
Drug Resistance, Multiple, Viral
1
2010
6
0.050
Why?
Quality Control
1
2010
71
0.050
Why?
Selection, Genetic
1
2010
14
0.050
Why?
Placebos
1
2010
185
0.050
Why?
Viremia
1
2009
36
0.040
Why?
Cell Division
1
1992
773
0.040
Why?
Statistics, Nonparametric
1
2010
269
0.040
Why?
Least-Squares Analysis
1
2008
29
0.040
Why?
New York
2
1999
1378
0.040
Why?
Nonlinear Dynamics
1
2008
35
0.040
Why?
Adolescent
2
1993
5044
0.040
Why?
Monte Carlo Method
1
2008
57
0.040
Why?
Acute Disease
1
2009
591
0.040
Why?
Lopinavir
1
2007
16
0.040
Why?
Ritonavir
1
2007
15
0.040
Why?
Safety
2
1995
106
0.040
Why?
Developed Countries
1
2006
5
0.040
Why?
Pyrimidinones
1
2007
21
0.040
Why?
Infant, Newborn
2
1995
1836
0.040
Why?
Maternal-Fetal Exchange
1
2006
139
0.030
Why?
Herpesvirus 4, Human
1
2006
66
0.030
Why?
Young Adult
1
2010
1084
0.030
Why?
Cytomegalovirus
1
2006
85
0.030
Why?
Fibroblasts
2
1992
545
0.030
Why?
Enzyme-Linked Immunosorbent Assay
1
2006
472
0.030
Why?
Prospective Studies
1
2009
1696
0.030
Why?
Algorithms
1
2008
543
0.030
Why?
Pharmacogenetics
1
2003
10
0.030
Why?
Vesicular stomatitis Indiana virus
1
2003
12
0.030
Why?
Peptides
1
2006
293
0.030
Why?
HIV Seropositivity
1
2003
36
0.030
Why?
Protease Inhibitors
1
2003
42
0.030
Why?
Chronic Disease
1
2006
554
0.030
Why?
Health Planning Guidelines
1
2003
24
0.030
Why?
Transcription, Genetic
2
1992
824
0.030
Why?
HLA Antigens
1
2003
98
0.030
Why?
Patient Compliance
1
2003
177
0.030
Why?
Methylation
1
2001
48
0.030
Why?
Recurrence
2
1990
697
0.030
Why?
Interleukin-5
1
2001
40
0.030
Why?
Capsid Proteins
1
2001
32
0.020
Why?
beta 2-Microglobulin
1
2000
19
0.020
Why?
Species Specificity
1
2001
342
0.020
Why?
Th1 Cells
1
2000
70
0.020
Why?
Polyneuropathies
1
2000
42
0.020
Why?
Th2 Cells
1
2000
91
0.020
Why?
Respiration
1
2000
181
0.020
Why?
Interleukin-4
1
2000
160
0.020
Why?
Europe
1
1999
77
0.020
Why?
Outpatient Clinics, Hospital
1
1999
44
0.020
Why?
Risk Assessment
1
2003
875
0.020
Why?
Cervix Uteri
1
1999
65
0.020
Why?
Lymphocyte Activation
1
2001
414
0.020
Why?
Sex Characteristics
1
2000
141
0.020
Why?
World Health
1
1999
65
0.020
Why?
Antibodies, Viral
1
2001
456
0.020
Why?
Transfection
1
2001
887
0.020
Why?
Heart Rate
1
2000
457
0.020
Why?
Vaccines, Synthetic
1
1997
88
0.020
Why?
Cognition Disorders
1
2000
291
0.020
Why?
Cryosurgery
1
1996
41
0.020
Why?
Cross-Sectional Studies
1
1999
676
0.020
Why?
Dose-Response Relationship, Drug
1
1999
1142
0.020
Why?
Longitudinal Studies
1
1997
413
0.020
Why?
United States
1
2003
2847
0.020
Why?
Combined Modality Therapy
1
1996
491
0.020
Why?
Prognosis
1
1996
1078
0.010
Why?
3T3 Cells
1
1992
75
0.010
Why?
Epithelium
1
1992
231
0.010
Why?
Bisexuality
1
1990
11
0.010
Why?
Injections, Subcutaneous
1
1990
93
0.010
Why?
Homosexuality
1
1990
25
0.010
Why?
Epithelial Cells
1
1992
332
0.010
Why?
Infant
1
1995
2320
0.010
Why?
Risk Factors
1
1996
2331
0.010
Why?
Sex Factors
1
1990
613
0.010
Why?
Recombinant Proteins
1
1990
770
0.010
Why?
Time Factors
1
1995
3234
0.010
Why?
Cell Differentiation
1
1992
1127
0.010
Why?

Visualizations


Demeter's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department